Summit Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Summit Therapeutics Inc. (SMMT) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $5.68 million as of 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2023-11-07
- 2023-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $5.68M.
- 2023-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $12.78M.
- 2023-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $5.12M.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $29.66M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value |
|---|---|
| 2023-09-30 | $5.68M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $12.78M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $5.12M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $29.66M 10-K · filed 2023-03-09 |
| 2022-09-30 | $527.00K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-11 |
| 2022-03-31 | $424.00K 10-Q · filed 2022-05-11 |
| 2021-12-31 | $712.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $8.60M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $18.60M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $12.90M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $6.64M 10-K/A · filed 2022-12-21 |
| 2020-09-30 | $3.80M 10-Q · filed 2020-11-16 |
| 2020-06-30 | $2.60M 8-K · filed 2020-09-29 |
| 2019-12-31 | $0.00 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |